Safety And Efficacy Of Vibostolimab, An Anti-Tigit Antibody, Plus Pembrolizumab In Patients With Anti-Pd-1/Pd-L1-Naive NsclcJ. Niu,A. Nagrial,M. Voskoboynik, H. C. Chung,D. H. Lee,M-J. Ahn,T. M. Bauer,A. Jimeno,V. Chung, K. F. Mileham, E. Chartash,D. Chen,J. Healy, M. Rajasagi,C. Maurice-DrorAnnals of Oncology(2020)引用 20|浏览28暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要